Please provide your email address to receive an email when new articles are posted on . Any bleeding event regardless of severity can adversely impact a patient. Factor XI and XIa inhibitors in ...

A new guide offers recommendations for the nonsurgical management of major hemorrhage, which is a challenging clinical problem. Major hemorrhage is a significant cause of death and can occur in a ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...

Please provide your email address to receive an email when new articles are posted on . Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran ...

Two of three commonly prescribed non-vitamin K oral anticoagulants (NOACs)—dabigatran and apixaban—have similar rates of major bleeding compared with aspirin, a large systematic review and ...

In stroke patients with atrial fibrillation (AF) and cardiovascular disease (CVD), adding an antiplatelet to an oral anticoagulant (OAC) does not reduce ischemic events and more than doubles bleeding ...